· 2022 ICD-10-CM Diagnosis Code Z20.6 Contact with and (suspected) exposure to human immunodeficiency virus [HIV] 2016 2017 2018 2019 2020 2021 2022 Billable/Specific Code Z20.6 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes.
· ICD-10 codes for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP). PrEP. Z20.6 Contact with and (suspected) exposure to HIV; Z20.2 Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission; Z11.3 Encounter for screening for infections with a predominantly sexual mode of transmission
16 rows · PrEP-Related Codes — Initial Visit Coding for: ICD-10 Code Description Visit Z20.6 Contact ...
12 rows · HIV Screening CPT and ICD -10 Codes TEST PRODUCT PTEST RODUCT Code Rapid Test Modifier ...
52 will replace Z11. 59 (Encounter for screening for other viral diseases), which the CDC previously said should be used when patients being screened for COVID-19 have no symptoms, no known exposure to the virus, and test results that are either unknown or negative.
Certain conditions have both an underlying etiology and multiple body system manifestations due to the underlying etiology. For such conditions, ICD-10-CM has a coding convention that requires the underlying condition be sequenced first followed by the manifestation.
PEP (post-exposure prophylaxis) means taking medicine to prevent HIV after a possible exposure. PEP should be used only in emergency situations and must be started within 72 hours after a recent possible exposure to HIV.
Patients with an HIV-related illness should be coded to 042, Human Immunodeficiency Virus {HIV} Disease. Patients with physician-documented asymptomatic HIV infections who have never had an HIV-related illness should be coded to V08, Asymptomatic Human Immunodeficiency Virus {HIV} Infection.
Once a patient is coded to B20, they will always have B20 coded on their record; they will never go back to being coded using the asymptomatic code Z21. Code Z21 is used for patients who are asymptomatic, meaning they are HIV positive but have never had an HIV-related condition.
Following ICD-10 guidelines, if a patient has or has had an HIV related condition, use B20 AIDS. If the patient has a positive HIV status, without symptoms or related conditions, use Z21.
Telatri. Telatri is indicated for the treatment of HIV-1 infection in adults aged 18 years and older.
Yes you can. TLD is a combination that can be used as PEP and for the management of active HIV infection. PEP stands for post exposure prophylaxis. PEP is used to prevent established infection after exposure.
Z20.2 Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission
The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) coding system does not designate specific codes for PrEP or PEP related services. The codes listed here are options for providers to use when discussing and prescribing PrEP and PEP.
Diagnosis of HIV infection is primarily made through the use of serologic assays. These assays take one of two forms: antibody detection assays and specific HIV antigen (p24) procedures. The antibody assays are usually enzyme immunoassays (EIA) which are used to confirm exposure of an individual's immune system to specific viral antigens. These assays may be formatted to detect HIV-1, HIV-2, or HIV-1 and 2 simultaneously and to detect both IgM and IgG. When the initial EIA test is repeatedly positive or indeterminant, an alternative test is used to confirm the specificity of the antibodies to individual viral components. The most commonly used method is the Western Blot.
Diagnostic testing to establish HIV infection may be indicated when there is a strong clinical suspicion supported by one or more of the following clinical findings:
The patient has signs and symptoms of acute retroviral syndrome with fever, malaise, lymphadenopathy, and skin rash.
If initial serologic tests are HIV EIA negative and there is no indication for confirmation of infection by viral RNA detection, the interval prior to retesting is 3-6 months.
HIV antibody testing in the United States is usually performed using HIV-1 or HIV-½ combination tests. HIV-2 testing is indicated if clinical circumstances suggest HIV-2 is likely (that is, compatible clinical findings and HIV-1 test negative). HIV-2 testing may also be indicated in areas of the country where there is greater prevalence of HIV-2 infections.
In several unique situations, serologic testing alone may not reliably establish an HIV infection. This may occur because the antibody response (particularly the IgG response detected by Western Blot) has not yet developed (that is, acute retroviral syndrome), or is persistently equivocal because of inherent viral antigen variability. It is also an issue in perinatal HIV infection due to transplacental passage of maternal HIV antibody. In these situations, laboratory evidence of HIV in blood by culture, antigen assays, or proviral DNA or viral RNA assays, is required to establish a definitive determination of HIV infection.
The HIV antigen tests currently have no defined diagnostic usage.